

# Expression of Cell Cycle–Related Genes With Cytokine-Induced Cell Cycle Progression of Primitive Hematopoietic Stem Cells

Peter J. Quesenberry, Gerri J. Dooner, Michael Del Tatto, Gerald A. Colvin, Kevin Johnson, and Mark S. Dooner

Primitive marrow lineage-negative rhodamine low and Hoechst low (LRH) stem cells isolated on the basis of quiescence respond to the cytokines thrombopoietin, FLT3L, and steel factor by synchronously progressing through cell cycle. We have now profiled the mRNA expression, as determined by real-time RT-PCR, of 47 hematopoietic or cell cycle-related genes, focusing on the variations in the cell cycle regulators with cycle transit. LRH stem cells, at isolation, showed expression of all interrogated genes, but at relatively low levels. In our studies, there was a good deal of consistency with regard to cell cycle regulatory genes involved in the G1/S progression point of LRH murine stem cells. The observed pattern of expression of cyclin A2 is consistent with actions at these phases of cell cycle. Minimal elevations were seen at 16 h with higher elevations at 24, 32, 40, and 48 h times encompassing S, G2, and M phases. CDK2 expression pattern was also consistent with a role in G1/S transition with a modest elevation at 24 h and more substantial elevation at 32 h. The observed pattern of expression of cyclin F mRNA with marked elevations at 16–40 h was also consistent with actions in S and G2 phases. Cyclin D1 expression pattern was less consistent with its known role in G1 progression. The alterations in multiple other cell cycle regulators were consistent with previous information obtained in other cell systems. The cycle regulatory mechanics appears to be preserved across broad ranges of cell types.

## Introduction

**H**EMATOPOIETIC STEM CELL GENE expression has been evaluated in different settings. We have focused on gene expression in a stem cell population purified on the basis of quiescence and then induced to synchronously transit cell cycle by *in vitro* exposure to thrombopoietin (TPO), FLT3L, and steel factor. We have studied lineage-negative rhodamine 123 low Hoechst 33342 low (LRH) murine stem cells purified on the basis of quiescence, utilizing depletion of lineage-positive cells and low staining with rhodamine 123 and Hoechst 33342 supra vital dyes [1–4]. This stem cell population is separated on the basis of quiescence and is equivalent in long-term multilineage engraftment and progenitor generation to any of the other described marrow hematopoietic stem cell populations. Approximately 1 in 4 cells will repopulate and 80%–90% will give rise to multi-cytokine-responsive high-proliferative potential colony-forming cells (HPP-CFC) *in vitro*; the latter constituting one of the best

surrogates for long-term engraftable stem cells [5–7]. We have previously shown that when this population of murine stem cells is exposed to IL-3, IL-6, IL-11, and steel factor *in vitro* in non-adherent flasks that there is a reproducible and synchronous progression from dormancy through cell cycle [8]. The first cycle from dormancy takes approximately 38–40 h to complete, while subsequent synchronous cycles (out to 5 cycles) are about 5–6 h in length. Previous studies have further established a number of reversible functional phenotype shifts with cycle progression. We have shown that short- and long-term engraftment [9,10], adhesion protein expression [11,12], cytokine receptor expression [13], and marrow homing [14] and differentiation [15] show reversible shifts in phenotype. We have also shown that progenitor numbers vary inversely with engraftable stem cell content with cycle passage, terming this a stem cell inversion [16]. In work with murine LRH stem cells, employing 3' end PCR differential display analysis, we interrogated these

---

Rhode Island Hospital and the Brown Medical School, Division of Hematology/Oncology, Department of Medicine, Providence, Rhode Island.

cells at isolation (quiescent) and compared gene expression to lineage-positive marrow cells. We identified a set of 637 transcripts expressed in stem cells and not expressed in lineage-positive cells [17]. We evaluated a subset of these stem cell-specific genes in freshly isolated LRH stem cells (time 0) and in the same set of cells after 48 h of culture in IL-3, IL-6, IL-11, and steel factor. A major shift in gene expression was found with many genes active in LRH at time 0 but turned off at 48 h and other genes inactive at time 0 and turned on at 48 h. These observations indicated that there was a shifting gene expression profile with cycle passage and that this correlated with changes in engraftment efficiency. In more recent studies, we used real-time RT-PCR to determine gene expression through cycle in the "cycling" stem cell population of lineage-negative Sca-1<sup>+</sup> marrow cells [18]. This population of putative stem cells has about 20% in S/G2/M at isolation, but progresses tightly through cell cycle upon exposure to IL-3, IL-6, IL-11, and steel factor. Conversely, LRH cells have a very low percentage of cells in S/G2/M at isolation. Here, we studied mRNA for a variety of cell surface epitopes and transcriptional regulators at different times in cytokine culture equating with different times in cell cycle. At isolation, these cycling stem cells expressed almost all cell surface markers and transcription factors studied, including receptors for granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage CSF, and IL-7. With cycle transit some transcripts, including CD34, CD45R, c-kit, Gata1, Gata2, Ikaros, and FOG showed stable expression over time, despite previously documented alterations in phenotype, while others evidenced variation of expression between and within experiments. The latter included Sca-1, Mac-1, c-fms, c-mpl, Tal-1, endoglin, and CD4. Altogether, these studies on lineage-negative Sca-1<sup>+</sup> stem cells showed that stem cells at isolation expressed a wide variety of genes and, with cell cycle transit, some of the genes showed remarkable and variable (between experiments) shifts.

We have now characterized LRH cells progressing through cell cycle under cytokine stimulation as to expression of intrinsic cell cycle regulatory genes. This provides the first cell cycle regulatory gene profile of a population of primitive stem cell synchronously progressing through cell cycle.

## Materials and Methods

### Animals

Six- to eight-week-old congenic male B6.SJL-PtprcaPep3b/Boy.J (B6.SJL) were purchased from Jackson Lab (Bar Harbor, ME). All animals were housed in micro-insulator cages, in a conventional clean facility for at least 1 week prior to experimental use. The animals in this Animal Care Committee approved study were maintained in accordance with the guidelines of the Institutional Animal Care and Use Committee of Rhode Island Hospital and recommendations in the Guide for the care and use of laboratory animals. All animals were 6–8 weeks of age at the time of bone marrow harvest.

### Isolation of whole bone marrow

Six- to 8-week-old male mice were sacrificed. Bone marrow was collected from femurs, tibiae, iliac crests, and spines by grinding bones in phosphate-buffered saline (PBS)

supplemented with 5% heat-inactivated fetal calf serum (HI FCS; Hyclone, Logan, VT) and 1% penicillin/streptomycin (P/S; Life/Technologies/Gibco/BRL) using a mortar and pestle. The bone fragments were washed multiple times and the supernatant cell suspension and wash fractions filtered through a 40- $\mu$ m nylon filter (Becton Dickinson, Franklin Lakes, NJ) to remove large bone particles. High lipid concentrations were reduced by centrifugation and resuspension of the cells in fresh buffer. The cells were incubated at 4°C for 5 min, so that small bone particles could settle out. The cell supernatant, depleted of these fragments, was then diluted to 10<sup>7</sup> cells/mL PBS with 5% HI FCS and 1% penicillin/streptomycin (PBS buffer).

### LRH hematopoietic stem cell (HSC) purification


A low-density fraction ( $1.320 \pm 0.001$  g/mL) of the whole bone marrow was isolated on Optiprep (Accurate Chemical and Scientific Corporation, Westbury, NY). The cells were lineage-depleted with the following primary rat antibodies: anti-B220, anti-MAC-1, anti-GR1, anti-Lyt-2, anti-L3T4, and Ter119 (BD PharMingen, San Diego, CA). Each batch of antibody was evaluated by flow cytometry analysis for the concentration, which resulted in the greatest shift in mean channel fluorescence and/or the greatest percentage of positive cells detected. The optimal dilution for each antibody was at a final concentration of 0.1  $\mu$ g/10<sup>6</sup> cells (0.5  $\mu$ g/10<sup>6</sup> cells for GR-1). After a 15-min incubation on ice, the labeled cells were washed in 1 $\times$  Dulbecco's phosphate-buffered saline, without calcium or magnesium chloride (PBS; Invitrogen Corp., Carlsbad, CA), 5% heat-inactivated fetal calf serum (HI FCS; Hyclone, Logan, UT), and resuspended in PBS buffer. The cells were incubated with washed sheep anti-rat IgG-conjugated immunomagnetic polystyrene spheres (M-450 Dynabeads; Dynal, Lake Success, NY) at 4°C for 20 min by adding beads in a drop-like fashion to obtain a 1:5 bead to cell ratio. The beads were suspended in PBS buffer and, when added to the cells, resulted in 1.5 times the original cell volume. After the 20-min incubation, immunomagnetic bead-rosetted cells were removed using a magnetic particle concentrator (DynaL, MPC-6), and the unrosetted cells remaining in suspension were harvested by pipette. The lineage-depleted cells were labeled with rhodamine 123 at a concentration of 0.1 mg/mL and Hoechst 33342 at 10 mM. Cells were incubated in the dark for 30 min at 37°C, washed, and followed by an additional incubation for 20 min at 37°C, allowing time for efflux of rhodamine. The last incubation was carried out twice before sorting. A population with both low expression of Hoechst and rhodamine fluorescence was isolated by FACS using a BD Cytosia InFlux high-speed cell sorter (BD Biosciences San Jose, CA).

### LRH cultures

LRH marrow cells were established in Teflon (non-adherent) bottle cultures with DMEM + 15% HI FCS + 1% P/S + 1% L-glutamine and cytokines at the following concentrations: thrombopoietin (TPO) 200 ng/mL, FLT3L 100 ng/mL, and steel factor 50 ng/mL. Cells were cultured at approximately  $1 \times 10^3$  cells/mL in Teflon bottles at 37°C, 5% CO<sub>2</sub> in a humidified water-jacketed incubator (Forma Scientific, Marietta, OH). Gene expression was evaluated immediately (time 0, before culture), and in different experiments at 1, 2, 3, 16, 24, 32, 40, and 48 h.

TABLE 1. TaqMan® ASSAYS

Assay ID	Gene	Description
Mm00484410_m1	Fli1	Friend leukemia integration 1, Gene mCG14021 Celera Annotation
Mm00494336_m1	Zfp1	Zinc finger protein, multitype 1, Gene mCG131388 Celera Annotation
Mm00487656_m1	Mdm2	Transformed mouse 3T3 cell double minute 2, Gene mCG3393 Celera Annotation
Mm00452747_m1	Mki67ip	Mki67 (FHA domain) interacting nucleolar phosphoprotein, Gene mCG3617 Celera Annotation
Mm00488140_m1	Sfp1	SFFV proviral integration 1, Gene mCG13483 Celera Annotation
Mm00433966_m1	Hoxa10	Homeo box A10, Gene mCG121167 Celera Annotation
Mm00432448_m1	Cdkn1a	Cyclin-dependent kinase inhibitor 1A (P21), Gene mCG126433 Celera Annotation
Mm00494449_m1	Cdkn2a	Cyclin-dependent kinase inhibitor 2A, Gene mCG123699 Celera Annotation
Mm00443919_m1	Ccnc	Cyclin C, Gene mCG4143 Celera Annotation
Mm00485474_m1	Rad21	RAD21 homolog ( <i>Schizosaccharomyces pombe</i> ), Gene mCG19537 Celera Annotation
Mm00484804_m1	Mcm2	Minichromosome maintenance deficient 2 mitotin ( <i>Saccharomyces cerevisiae</i> ), Gene mCG130613 Celera Annotation
Mm00479445_m1	Nfatc1	Nuclear factor of activated T cells, cytoplasmic, calcineurin-dependent 1, Gene mCG18180 Celera Annotation
Mm00487905_m1	Rad51	RAD51 homolog ( <i>S. cerevisiae</i> ), Gene mCG6194 Celera Annotation
Mm00443947_m1	Cdk2	Cyclin-dependent kinase 2, Gene mCG18668 Celera Annotation
Mm00440464_m1	Nek2	NIMA (never in mitosis gene a)-related expressed kinase 2, Gene mCG14118 Celera Annotation
Mm00801867_m1	Mcm3	Minichromosome maintenance deficient 3 ( <i>S. cerevisiae</i> ), Gene mCG119126 Celera Annotation
Mm00432359_m1	Ccnd1	Cyclin D1, Gene mCG21251 Celera Annotation
Mm00487888_m1	Rad17	RAD17 homolog ( <i>S. pombe</i> ), Gene mCG116114 Celera Annotation
Mm00438064_m1	Ccna2	Cyclin A2, Gene mCG14064 Celera Annotation
Mm00432385_m1	Ccnf	Cyclin F, Gene mCG12800 Celera Annotation
Mm00501741_m1	Myb	Myeloblastosis oncogene, Gene mCG140750 Celera Annotation
Mm00803251_m1	Rbl1	Retinoblastoma-like 1 (p107), Gene mCG21972 Celera Annotation
Mm00514160_m1	E2f4	E2F transcription factor 4, Gene mCG141649 Celera Annotation
Mm00483162_m1	Cdc25a	Cell division cycle 25 homolog A ( <i>S. pombe</i> ), Gene mCG2036 Celera Annotation
Mm00803077_m1	Notch2	Notch gene homolog 2 ( <i>Drosophila</i> ), Gene mCG11101 Celera Annotation
Mm00487954_m1	Rbl2	Retinoblastoma-like 2, Gene mCG126509 Celera Annotation
Mm00624964_m1	E2f2	E2F transcription factor 2, Gene mCG5146 Celera Annotation
Mm00482296_m1	Cdk5rap1	CDK5 regulatory subunit-associated protein 1, Gene mCG3682 Celera Annotation
Mm00465434_m1	Pkd1	Polycystic kidney disease 1 homolog, Gene mCG12835 Celera Annotation
Mm00432337_m1	Ccna1	Cyclin A1, Gene mCG19561 Celera Annotation
Mm00437762_m1	B2m	$\beta$ 2-Microglobulin, Gene mCG11606 Celera Annotation
Mm00607939_s1	Actb	Actin, beta, cytoplasmic, Gene mCG23209 Celera Annotation
Mm9999915_g1	Gapdh	Glyceraldehyde-3-phosphate dehydrogenase, Gene mCG1045551 Celera Annotation, Gene mCG4178 Celera Annotation, Gene mCG1030816 Celera Annotation, Gene mCG8723 Celera Annotation, Gene mCG125819 Celera Annotation, Gene mCG130520 Celera Annotation, Gene mCG19641 Celera Annotation, Gene mCG130428 Celera Annotation, Gene mCG142399 Celera Annotation, Gene mCG114986 Celera Annotation, Gene mCG1217 Celera Annotation, Gene mCG115979 Celera Annotation, Gene mCG112896 Celera Annotation, Gene mCG1037 Celera Annotation, Gene mCG121685 Celera Annotation, Gene mCG9609 Celera Annotation, Gene mCG19420 Celera Annotation, Gene mCG130206 Celera Annotation, Gene mCG117943 Celera Annotation, Gene mCG120614 Celera Annotation, Gene mCG133580 Celera Annotation, Gene mCG114112 Celera Annotation, Gene mCG134295 Celera Annotation, Gene mCG115100 Celera Annotation, Gene mCG113945 Celera Annotation, Gene mCG7218 Celera Annotation, Gene mCG49966 Celera Annotation, Gene mCG116755 Celera Annotation
Mm00448463_m1	Ptprc	Protein tyrosine phosphatase, receptor type, C, Gene mCG5383 Celera Annotation
Mm00440310_m1	Mpl	Myeloproliferative leukemia virus oncogene, Gene mCG8865 Celera Annotation
Mm00438996_m1	Flt3	FMS-like tyrosine kinase 3, Gene mCG121644 Celera Annotation
Mm00438328_m1	Csf2	Colony-stimulating factor 2 (granulocyte-macrophage), Gene mCG13784 Celera Annotation
Mm00432735_m1	Csf3r	Colony-stimulating factor 3 receptor (granulocyte), Gene mCG10884 Celera Annotation
Mm00438331_g1	Csf2ra	Colony-stimulating factor 2 receptor, alpha, low-affinity (granulocyte-macrophage), Gene mCG20697 Celera Annotation
Mm00492300_m1	Gata2	GATA-binding protein 2, Gene mCG130615 Celera Annotation
Mm00484678_m1	Gata1	GATA-binding protein 1, Gene mCG3964 Celera Annotation
Mm00801891_m1	Nfe2	Nuclear factor, erythroid-derived 2, Gene mCG15671 Celera Annotation
Mm00456421_m1	Ikzf1	IKAROS family zinc finger 1, Gene mCG3994 Celera Annotation



**FIG. 1.** Endogenous control through cell cycle. Average cycle threshold (CT) values for  $\beta$ 2-microglobulin are displayed as the rhodamine low and Hoechst low (LRH) stem cells are samples at various points in cell cycle transit. Error bars represent the standard error between experiments where the number of experiments ( $n$ ) is indicated for each time point.

### Cell cycle evaluation with propidium iodide staining

LRH populations were analyzed for cell cycle status at different time points in culture. Cellular DNA was labeled with propidium iodide (Stain DNA Assay PI [RPI-2], Nova Century Scientific), and percentage of cells stained was analyzed on a MoFlo cell sorter (Cytomation, Fort Collins, CO) to assess the cycling status of the cells at different times in culture.

### Gene analysis

Fold difference in gene expression was analyzed and expressed relative to the 0-h control. RNA was isolated from LRH cells at various points in cell cycle using the manufacturer's protocol (PicoPure™ RNA Isolation Kit, Arcturus Mt. View, CA). Reverse transcription was performed with the high-capacity cDNA reverse transcription kit (Applied Biosystems [ABI], Foster City, CA) using manufacturer's protocol for a 50- $\mu$ L total reaction. Real-time PCR was performed using pre-developed Taqman Assays (ABI), targeted to mRNA in a 20- $\mu$ L reaction mixture containing 2 $\times$  Taqman Universal PCR Master Mix (ABI) and equal amounts of cDNA with nuclease-free water. Murine  $\beta$ 2-microglobulin was used as an endogenous control. Samples were run, using the standard default thermal profile (7900HT Sequence Detection System, ABI). TaqMan® custom array was used for larger samplings of the genes. Relative gene expression was calculated with the comparative CT method. In this method, the relative quantitation of the target gene is normalized to an endogenous control ( $\beta$ 2-microglobulin) and is expressed relative to a calibrator sample (0-h control) as  $2^{-\Delta\Delta Ct}$  or fold difference, where  $\Delta Ct = Ct$  of target gene  $- Ct$  of endogenous control gene and  $\Delta\Delta Ct = \Delta Ct_{\text{target gene}} - \Delta Ct_{\text{calibrator}}$ . Information on specific TaqMan® assays is detailed in Table 1.

### Statistics

Data was evaluated using an unpaired Student's *t*-test.

### Results

We first established the stability of our gene expression system. Figure 1 shows expression of our control

housekeeper gene,  $\beta$ 2-microglobulin, as indicated by cycle threshold (CT) values in multiple experiments at time 0 and after various times of cytokine culture. The relative reproducibility is shown by the very tight standard errors. Test values were all normalized to  $\beta$ 2-microglobulin expression values.

In order to present fold differences that varied over a wide range especially when the comparator was very low, we have created a value range to encompass the varied fold differences and for ease of presentation. This is presented in Table 2.

We have previously mapped the cell cycle status of LRH cells stimulated with thrombopoietin, FLT3L, and steel factor using propidium iodide [15]. At time 0, there are either very few or no LRH stem cells in S phase, and hence there is a highly synchronous progression through cycle. S phase progression probably occurs at around 15–16 h and, by 40 h, essentially all the LRH cells are in S phase.


In Figure 2, we present the absolute  $\Delta Ct$  values for the cell cycle genes to give an indication of baseline gene expression. In general, at time 0 in freshly purified LRH stem cells, expression of the cycle regulatory genes was low but quite varied. It is from this base that we are assessing the relative changes of gene expression over time.

Cyclin gene expression in LRH stem cells at different times in culture equating with different cell cycle points

**TABLE 2.** NORMALIZATION SCALE FOR GENE EXPRESSION VALUES

<i>Fold Difference</i>	<i>Normalization</i>
<0.01–0	–4
>0.01–0.05	–3
>0.05–0.50	–2
>0.5–0.99	–1
0	0
>1–1.99	1
2–5	2
5–10	3
10–20	4
20–100	5
100–1,000	6
>1,000	7





**FIG. 2.** Absolute gene expression at isolation. Individual  $\Delta$ CT values, which have been corrected with the endogenous control cycle threshold (CT) value, are expressed at isolation (0 h in culture).

are shown in Figure 3. The striking elevations at cyclins A2 and F, at times of G1/S cycle transit and through the G2/M phases, are apparent. These changes were highly significant ( $P$  values in legend).


Expression of further cell cycle regulatory genes is presented in Figure 4. Here, correlations with function are complex and sometimes not clear. However, many of the expression patterns continued to be consistent with the presumed place of these entities in cell cycle regulation.

## Discussion


Cyclins and cyclin-dependent kinases play complex roles in the progression of cell cycle [19], and their role may vary with different cell types or species under investigation. Much of this complexity is well-summarized in work by Sanchez and Dynlacht [20].

In our studies, there was a good deal of consistency with regard to cell cycle regulatory genes involved in the G1/S

progression point of LRH murine stem cells. Most striking was the highly reproducible and quite striking elevations of cyclins A2 and F with progression from G1 through S phase. Cyclin A2 binds and activates CDC2 and CDK2 promoting transitions at G1/S and G2/M phases [21–23]. The observed pattern of expression in 6 separate experiments is consistent with actions at these phases of cell cycle. No elevations were seen at 1, 2, and 3 h; minimal elevations were seen at 16 h with higher elevations at 24, 32, 40, and 48 h times encompassing S, G2, and M phases. CDK2 expression pattern was also consistent with a role in G1/S transition with a modest elevation at 24 h and more substantial elevation at 32 h. CDK2 interacts with a broad range of cyclins and also plays a role in chromosome stability [20]. Cyclin F belongs to the F box family of proteins that make up one of the 4 subunits of the ubiquitin ligase complex [24,25]. This latter is involved in phosphorylation-dependent ubiquitination. In general, this is felt to be involved in control of cell cycle in S and G2 phases. This is also consistent with the observed pattern of



**FIG. 3.** Mapping cyclin gene expression. Fold differences relative to 0-h control in rhodamine low and Hoechst low (LRH) stem cells cultured in TPO, FLT3, and steel factor. Number of experiments ( $n$ ) is 2 for all values except 32-h samples ( $n = 6$ ): cyclin D1; cyclin A1; cyclin A2; 40-h samples ( $n = 4$ ); 48-h samples ( $n = 3$ ). Statistical significance by Student's  $t$ -test: \* $P \leq 0.05$ ;  $^{\dagger}P < 0.01$ ;  $^{\ddagger}P \leq 0.005$ .



**FIG. 4.** Normalized gene expression of rhodamine low and Hoechst low (LRH) stem cells through cycle. Cells cultured in TPO, FLT3, SCF, and analyzed at 0 through 32 h. Gene expression is represented as fold differences relative to the 0-h control. Variations in gene expression are shown with cycle transit. Statistical significance by Student's *t*-test: \* $P \leq 0.05$ .

expression of cyclin F mRNA with no elevations at 1, 2, and 3 h and marked elevations at 16–40 h but not at 48 h when the cells have entered their next cycle transit. These findings are consistent with findings in multiple other cell systems.

Cyclin D1 also showed increased expression in S phase, albeit not as pronounced as was seen with cyclins A2 and F. It did not show increased expression at 16 h, suggesting a lack of involvement in the G1/S transition. D1 also showed an increase at one point in G1 (2 h). Cyclin D1 expression pattern was less consistent with its known role in G1 progression [20,26]. Cyclin D has a role in repair of double-strand DNA breaks and mitosis. It did show moderately increased expression in S phase and through mitoses.

Cyclin C showed modest elevations in mid- to late S phase and through M phase consistent with its known role in mitotic growth [27,28].

Cyclin B2 showed modest elevations in S phase of the marrow stem cells [20,29,30]. Its probable role in G2/M transition was not really interrogated in these experiments.

Cyclin A1 showed marginal changes around baseline and, although this may be involved in control of cell cycle at the G1/S and G2/M transitions, the present data in murine marrow stem cells are more consistent with its role in control of germ-line meiotic cell cycle [31].

Given the complexity of the cell cycle regulatory network, any division into specific classes is of necessity relatively arbitrary. We have grouped the cyclin gene expression, and presented this in Figure 4. Cdkn2a, Myb, and Nfatc1 were grouped in G1 phase and G1/S transition. Nfatc1 probably has a major role with T cells [32], and it was at baseline or depressed in the hematopoietic stem cells with cycle transit. Myb expression was modestly increased in S phase consistent with its known role in hematopoietic stem cell proliferation [33]. Cdkn2a or p16INK4a expression was variably up at

1 and 24 h, but not increased at other time points. This interacts with cyclin-dependent kinases 4 and 6 and inhibits their ability to interact with cyclin D. It induces cell cycle arrest at G1 and G2/M checkpoints [34–36]. Its expression pattern fits with the generally successful cycle transit of LRH stem cells in these studies.

The next panel outlines cycle regulators involved in S phase relocation. Mcm2 is required for entry into S phase and cell replication. It is present and increased at 32 h into S phase. It is of interest that Rad51, Rad17, and Mcm3 are all involved with DNA damage/repair and are all elevated at multiple points in S phase at 16, 24, and 32 h. Whether this indicates that a percentage of the stem cells transiting cycle experience DNA damage and are possibly arrested for repair remains an open question [37].

In a related vein, putative checkpoint/arrest regulators including Cdk2, Mdm2, and Sesn2 showed variable and relatively minor changes through cycle except possibly for SESn2 at 32 h [38].

Finally, E2f1, E2f2, and E2f4 are lumped under regulation of cell cycle. There were relatively small elevations of E2f1 and E2f4 in S phase but, at most time points, its expression was below or at baseline, and it is not clear how these expressions fit into the cell cycle picture of hematopoietic stem cells.

Evaluation of the absolute cycle values at time 0 indicated relatively low but quite variable expression of the cell cycle regulators in LRH stem cells.

Altogether, these data give us a profile of cell cycle regulator mRNA expression with progress of primitive marrow hematopoietic stem cells through a cytokine-induced cell cycle transit. In general, based upon the described actions of these regulators, levels seen in the stem cells at different points in cycle were consistent with information obtained

in multiple other cell systems. Particularly striking and highly reproducible were the marked elevations of expression of cyclins A2 and F coincident with transition from G1 to S phase. The cycle regulatory mechanics appear to be preserved across broad ranges of cell types.

## Conclusion

Expression of cycle regulator genes at LRH stem isolation was very low and patterns of induction in general confirmed data from other cell systems. The G1/S transition was characterized by reproducible induction of cyclins A2 and F gene expression. These data provide a cycle regulator gene expression profile at different points in cycle transit of LRH stem cells.

## Acknowledgments

We wish to acknowledge Ms. Sandy Bibby, Coordinating Editor for the Division of Hematology/Oncology Scholarly Publications, Rhode Island Hospital, Providence, RI, for her role in editing this manuscript. This work was supported by 1 P20 RR025179-01, 7R01 HL073749-05.

## References

- Bertoncello I, GS Hodgson and TR Bradley. (1985). Multi-parameter analysis of transplantable hemopoietic stem cells. The separation and enrichment of stem cells homing to marrow and spleen on the basis of rhodamine 123 fluorescence. *Exp Hematol* 13:999.
- Baines P and JW Visser. (1983). Analysis and separation of murine bone marrow stem cells by H33342 fluorescence-activated cell sorting. *Exp Hematol* 11:701.
- Ploemacher RE and Brons NHC. (1988). Cells with marrow and spleen repopulating ability and forming spleen colonies on days 16, 12, and 8 are sequentially ordered on the basis of increasing rhodamine 123 retention. *J Cell Physiol* 36:531.
- Wolf NS, A Kone, GV Priestley and SH Bartelmez. (1993). In vivo and in vitro characterization of long-term repopulating primitive hematopoietic cells isolated by sequential Hoechst 33342-rhodamine123 FACS selection. *Exp Hematol* 21:614.
- McNiece IK, I Bertoncello, AB Kreigler and PJ Quesenberry. (1990). Colony-forming cells with high proliferative potential (HPP-CFC). *Int J Cell Cloning* 8:146-160.
- McNiece IK, BE Robinson and PJ Quesenberry. (1988). Stimulation of murine colony-forming cells with high proliferative potential by the combination of GM-CSF and CSF-1. *Blood* 72:191-195.
- Kriegler AB, SM Verschoor, D Bernardo and I Bertoncello. (1994). The relationship between different high proliferative potential colony-forming cells in mouse bone marrow. *Exp Hematol* 22:432-440.
- Reddy GP, CY Tiarks, L Pang, J Wu, CC Hsieh and PJ Quesenberry. (1997). Cell cycle analysis and synchronization of pluripotent hematopoietic progenitor stem cells. *Blood* 90:2293-2299.
- Habibian HK, SO Peters, CC Hsieh, J Wu, K Vergillis, CI Grimaldi, J Reilly, JE Carlson, AE Frimberger, FM Stewart and PJ Quesenberry. (1998). The fluctuating phenotype of the lymphohematopoietic stem cell with cell cycle transit. *J Exp Med* 188:393-398.
- Colvin GA, JF Lambert, JE Carlson, CI McAuliffe, M Abedi and PJ Quesenberry. (2002). Rhythmicity of engraftment and altered cell cycle kinetics of cytokine-cultured murine marrow in simulated microgravity compared with static cultures. *In Vitro Cell Dev Biol Anim* 38:343-351.
- Becker PS, SK Nilsson, Z Li, VM Berrios, MS Dooner, CL Cooper, CC Hsieh and PJ Quesenberry. (1999). Adhesion receptor expression by hematopoietic cell lines and murine progenitors: Modulation by cytokines and cell cycle status. *Exp Hematol* 27:533-541.
- Berrios VM, GJ Dooner, G Nowakowski, A Frimberger, H Valinski, PJ Quesenberry and PS Becker. (2001). The molecular basis for the cytokine-induced defect in homing and engraftment of hematopoietic stem cells. *Exp Hematol* 29:1326-1335.
- Reddy GP, CI McAuliffe, L Pang, PJ Quesenberry and I Bertoncello. (2002). Cytokine receptor repertoire and cytokine responsiveness of Ho<sup>dull</sup>/Rh<sup>dull</sup> stem cells with differing potentials for G<sub>1</sub>/S phase progression. *Exp Hematol* 30:792-800.
- Cerny J, M Dooner, C McAuliffe, H Habibian, K Stencil, V Berrios, J Reilly, J Carlson, AM Cerny, L D'Hondt, B Benoit, JF Lambert, G Colvin, S Nilsson, P Becker and PJ Quesenberry. (2002). Homing of purified murine lymphohematopoietic stem cells: a cytokine-induced defect. *J Hematother Stem Cell Res* 11:913-922.
- Colvin GA, MS Dooner, GJ Dooner, FM Sanchez-Guijo, DA Demers, M Abedi, M Ramanathan, S Chung, S Pascual and PJ Quesenberry. (2007). Stem cell continuum: directed differentiation hotspots. *Exp Hematol* 35:96-107.
- Colvin GA, JF Lambert, BE Moore, JE Carlson, MS Dooner, M Abedi, J Cerny and PJ Quesenberry. (2004). Intrinsic hematopoietic stem cell/progenitor plasticity: Inversions. *J Cell Physiol* 199:20-31.
- Lambert JF, M Liu, GA Colvin, M Dooner, CI McAuliffe, PS Becker, BG Forget, SM Weissman and PJ Quesenberry. (2003). Marrow stem cells shift gene expression and engraftment phenotype with cell cycle transit. *J Exp Med* 197:1563-1572.
- Dooner GJ, GA Colvin, MS Dooner, KW Johnson and PJ Quesenberry. (2008). Gene expression fluctuations in murine hematopoietic stem cells with cell cycle progression. *J Cell Physiol* 214:786-795.
- Kohn KW. (1999). Molecular interaction map of the mammalian cell cycle control and DNA repair systems. *Mol Biol Cell* 10:2703-2704.
- Sanchez I and BD Dynlacht. (2005). New insights into cyclins, CDKs and cell cycle control. *Semin Cell Dev Biol* 16:311-312.
- Blanchard JM. (2000). Cyclin A2 transcriptional regulation: modulation of cell cycle control at the G1/S transition by peripheral cues. *Biochem* 60:1179-1184.
- Barton KM and EM Levine. (2008). Expression patterns and cell cycle profiles of PCNA, MCM6, cyclin D1, cyclin A2, cyclin B1, and phosphorylated histone H3 in the developing mouse retina. *Dev Dyn* 237:672-682.
- Desdouets C, GH Thorensen and C Senamaud-Beaufort. (1999). cAMP-dependent positive control of cyclin A2 expression during G1/S transition in primary hepatocytes. *Biochem Biophys Res Commun* 261:118-122.
- Nakayama KI and K Nakayama. (2005). Regulation of the cell cycle by SCF-type ubiquitin ligases. *Semin Cell Dev Biol* 16:323-333.
- Nakayama KI and K Nakayama. (2006). Ubiquitin ligases: cell-cycle control and cancer. *Nat Rev Cancer* 6:369-381 [Review].
- Alao JP. (2007). The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention. *Mol Cancer* 6:24.
- Birkenbihl RP and S Subramani. (1995). The rad21 gene product of *Schizosaccharomyces pombe* is a nuclear, cell cycle-regulated phosphoprotein. *J Biol Chem* 270:7703-7711.
- Birkenbihl RP and S Subramani. (1992). Cloning and characterization of rad21 an essential gene of *Schizosaccharomyces pombe* involved in DNA double-strand-break repair. *Nucleic Acids Res* 20:6605-6611.
- Cude K, Y Wang, HJ Choi, SL Hsuan, H Zhang, CY Wang and Z Xia. (2007). Regulation of the G2-M cell cycle progression by the ERK5-NFkappaB signaling pathway. *J Cell Biol* 177:253-264.
- Bellanger S, A de Gramont and J Sobczak-Thepot. (2007). Cyclin B2 suppresses mitotic failure and DNA re-replication in

- human somatic cells knocked down for both cyclins B1 and B2. *Oncogene* 26:7175–7184.
31. Wolgemuth DJ. (2008). Function of cyclins in regulating the mitotic and meiotic cell cycles in male germ cells. *Cell Cycle* 7:3509–3513 [Review].
  32. Sumpter TL, KK Payme and DS Wilkes. (2008). Regulation of the NFAT pathway discriminates CD4+CD25+ regulatory T cells from CD4+CD25– helper T cells. *J Leukoc Biol* 83:708–717.
  33. Greig KT, S Carotta and SL Nutt. (2008). Critical roles for c-Myb in hematopoietic progenitor cells. *Semin Immunol* 20:247–256 [Review].
  34. Ch'ng S and ST Tan. (2009). Genetics, cellular biology, and tumor microenvironment of melanoma. *Front Biosci* 14:918–929 [Review].
  35. del Arroyo AG and G Peters. (2005). The Ink4a/Arf network—cell cycle checkpoint or emergency brake? *Adv Exp Med Biol* 570:227–247 [Review].
  36. Canepa ET, ME Scassa, JM Ceruti, MC Marazita, AL Carcagno, PF Sirkin and MF Ogara. (2007). INK4 proteins, a family of mammalian CDK inhibitors with novel biological functions. *IUBMB Life* 59:419–426 [Review].
  37. Humpal SE, DA Robinson and JE Krebs. (2009). Marks to stop the clock: histone modifications and checkpoint regulation in the DNA damage response. *Biochem Cell Biol* 87:243–253.
  38. Hay N. (2008). p53 strikes mTORC1 by employing sestrins. *Cell Metab* 8:184–185 [Review].

Address correspondence to:

*Dr. Peter J. Quesenberry  
Director, Division of Hematology/Oncology  
Rhode Island Hospital  
593 Eddy Street  
George 3  
Providence, RI 02903*

*E-mail: pquesenberry@lifespan.org*

Received for publication July 31, 2009

Accepted after revision September 23, 2009

Prepublished on Liebert Instant Online September 29, 2009